Ototoxicity and drugs of ingredients of etoposide - a phase IV clinical study of FDA data


Summary:

Ototoxicity is found among people who take drugs with ingredients of etoposide, especially for people who are female, 2-9 old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 57,579 people who have side effects when taking drugs with ingredients of etoposide from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Etoposide, Toposar, Vepesid.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.


On Jun, 28, 2022

57,579 people reported to have side effects when taking drugs with ingredients of etoposide.
Among them, 178 people (0.31%) have Ototoxicity


What is Ototoxicity?

Ototoxicity (damage to the ear) is found to be associated with 593 drugs and 325 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of etoposide cause Ototoxicity?

Time on drugs with ingredients of etoposide when people have Ototoxicity *:

  • < 1 month: 85.71 %
  • 1 - 6 months: 14.29 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Ototoxicity when taking drugs with ingredients of etoposide *:

  • female: 62.14 %
  • male: 37.86 %

Age of people who have Ototoxicity when taking drugs with ingredients of etoposide *:

  • 0-1: 14.55 %
  • 2-9: 47.27 %
  • 10-19: 8.18 %
  • 20-29: 9.09 %
  • 30-39: 12.73 %
  • 40-49: 0.0 %
  • 50-59: 3.64 %
  • 60+: 4.55 %

Conditions people have *:

  1. Gestational Trophoblastic Tumor: 47 people, 26.40%
  2. Retinoblastoma (tumour of retina): 47 people, 26.40%
  3. Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 18 people, 10.11%
  4. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 9 people, 5.06%
  5. Ovarian Cancer (cancer of ovary): 6 people, 3.37%
  6. Neoplasm Malignant (cancer tumour): 6 people, 3.37%
  7. Medulloblastoma (a fast-growing, high-grade tumour that always begins in the cerebellum): 5 people, 2.81%
  8. Neuroblastoma (a cancer that forms in your nerve tissue): 5 people, 2.81%
  9. Ovarian Neoplasm (tumour of ovary): 5 people, 2.81%
  10. Metastatic Choriocarcinoma (cancer of embryo covering cells can spread to other part): 3 people, 1.69%

Other drugs people take *:

  1. Dactinomycin: 54 people, 30.34%
  2. Cisplatin: 42 people, 23.60%
  3. Methotrexate: 39 people, 21.91%
  4. Ciclosporin: 35 people, 19.66%
  5. Carboplatin: 34 people, 19.10%
  6. Ifosfamide: 27 people, 15.17%
  7. Vincristine Sulfate: 12 people, 6.74%
  8. Cosmegen: 12 people, 6.74%
  9. Epirubicin Hydrochloride: 7 people, 3.93%
  10. Ondansetron: 6 people, 3.37%

Other side effects people have besides Ototoxicity *:

  1. Febrile Neutropenia (fever with reduced white blood cells): 17 people, 9.55%
  2. Interstitial Lung Disease: 15 people, 8.43%
  3. Hearing Loss: 15 people, 8.43%
  4. Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 14 people, 7.87%
  5. Bone Marrow Failure: 12 people, 6.74%
  6. Tinnitus (a ringing in the ears): 11 people, 6.18%
  7. Thrombocytopenia (decrease of platelets in blood): 10 people, 5.62%
  8. Pneumonia: 9 people, 5.06%
  9. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 8 people, 4.49%
  10. Malignant Neoplasm Progression (cancer tumour came back): 8 people, 4.49%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drugs with ingredients of etoposide, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on etoposide. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: